

**Prognostic value of the Residual Cancer Burden index according to breast cancer  
subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy.**

Anne-Sophie Hamy<sup>1,2</sup>, Lauren Darrigues<sup>3</sup>, Enora Laas<sup>3</sup>, Diane De Croze<sup>4</sup>, Lucian Topciu<sup>5</sup>,  
Giang-Thanh Lam<sup>3,6</sup>, Clémence Evrevin<sup>2</sup>, Sonia Rozette<sup>2</sup>, Lucie Laot<sup>3</sup>, Florence Lerebours<sup>2</sup>,  
Jean-Yves Pierga<sup>2,3</sup>, Marie Osdoit<sup>3</sup>, Matthieu Faron<sup>7</sup>, Jean-Guillaume Feron<sup>3</sup>, Marick Laé<sup>5</sup>,  
Fabien Reyat<sup>2,3,8</sup>

1. Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932  
Immunity and Cancer, Institut Curie, Paris, F-75248, France.
2. Department of Medical Oncology, Institut Curie, Saint-Cloud, F-92230, France.
3. Department of Surgery, Faculté de médecine Descartes, Université Paris, Institut  
Curie, Paris, F-75248, France.
4. Department of Tumor Biology, Institut Curie, Saint-Cloud, F-92230, France
5. Department of Tumor Biology, Institut Curie, Paris, F-75248, France.
6. Department of Gynecology and Obstetrics, Geneva University Hospitals, 30 bd de la  
Cluse, 3205 Geneva, Switzerland.
7. Department of biostatistics and epidemiology, INSERM 1018 CESP Oncostat team,  
Gustave Roussy Cancer Campus, 94800 Villejuif

† and ‡ : contributed equally to this work.

**Running title** : Prognostic value of the RCB index according to BC subtypes.

**Keywords**: Residual Cancer Burden – prognostic score - neoadjuvant chemotherapy -

**NOTE**: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.<sub>1</sub>

residual disease.

**Additional information:**

- **Corresponding author:** Pr Fabien REYAL, Institut Curie, Department of Surgery, 26 rue d’Ulm, 75005 Paris 00 33 144324087, 00 33 615271980, [fabien.reyal@curie.fr](mailto:fabien.reyal@curie.fr)
- **Declaration of Interests :** The authors declare no potential conflicts of interest.
- **Manuscript :** Abstract : 249 words – Text : 2632 words – Number of Figures : 5 – Number of tables : 4 – Number of Supplementary Tables : 7 .

**Novelty and impact statement:**

The residual cancer burden index (RCB) quantifies residual disease following neoadjuvant chemotherapy (NAC) and was developed as a prediction tool. The evaluation of its prognostic value in a large real-life cohort of breast cancer patients stratified according to the different subtypes of BC (Luminal, *HER2*-positive and triple negative (TNBCs)) could improve breast cancer patients’ prognosis by identifying those at a high risk of recurrence, who should be offered second line adjuvant therapies.

**Data availability statement:**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ABSTRACT (249 words):**

**Introduction:** The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evaluate the prognostic value of the RCB index depending on BC subtypes (Luminal, *HER2*-positive and triple negative (TNBCs)).

**Methods:** We retrospectively evaluated the RCB index on surgical specimens from a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012. We analyzed the association between RCB index and relapse-free survival (RFS), overall survival (OS) among the global population, after stratification by BC subtypes.

**Results:** 717 patients were included (luminal BC (n = 222, 31%), TNBC (n = 319, 44.5%), *HER2*-positive (n = 176, 24.5%)). After a median follow-up of 99.9 months, RCB index was significantly associated with RFS. The RCB-0 patients displayed similar prognosis when compared to the RCB-I group, while patients from the RCB-II and RCB-III classes were at increased risk of relapse (RCB-II *versus* RCB-0: HR=3.25 CI [2.1-5.1]  $p<0.001$ ; RCB-III *versus* RCB-0: HR=5.6 CI [3.5-8.9]  $p<0.001$ ). The prognostic impact of RCB index was significant for TNBC and *HER2*-positive cancers; but not for luminal cancers ( $P_{\text{interaction}} = 0.07$ ). The prognosis of RCB-III patients was poor (8-years RFS: 52.7%, 95% CI [44.8 – 62.0]) particularly in the TNBC subgroup, where the median RFS was 12.7 months.

**Conclusion:** RCB index is a reliable prognostic score. RCB accurately identifies patients at a high risk of recurrence (RCB-III) with TNBC or *HER2*-positive BC who must be offered second-line adjuvant therapies.

## INTRODUCTION

**Neoadjuvant chemotherapy (NAC)**, *i.e.* chemotherapy before surgery, is currently being used in poor prognosis breast carcinoma. Besides reducing tumor burden and enabling conservative breast surgery, NAC also provides a unique opportunity to evaluate the response of patients with breast cancer (BC) to different treatments. Pathologic complete response (pCR), defined as an absence of invasive cancer in the breast and axillary lymph nodes, is associated with better long-term survival, though its prognostic value is particularly important in highly aggressive tumors, such as triple negative breast cancer (TNBC) and *HER2*-positive BC (Cortazar et al., 2014).

However, since most of the tumors do not achieve pCR following NAC, this binary indicator gathers in a unique category the majority of the patients, thus precluding the opportunity to sharply predict their oncological outcome. While patients with pCR exhibit an excellent prognosis, a wide clinical heterogeneity remains within those patients failing to reach complete response, and the identification of patients with residual disease at a high risk of relapse is a substantial challenge. Hence, the subdivision of the BC population into several prognostic groups could help improving the prediction of survival benefits (Hatzis et al., 2013).

The Residual Cancer Burden (RCB) index has been developed in 2007 by Symmans and colleagues from the M.D. Anderson Cancer Center (MDACC) (Symmans et al., 2007a) to quantify residual disease following NAC. The RCB index combines pathological findings in the primary tumor bed and the regional lymph nodes to calculate a continuous index. This index is subdivided into four classes with an increasing amount of residual disease: RCB 0 (pCR), RCB-I, RCB-II, and RCB-III. Several prospective clinical studies (CALGB (Hylton et al., 2016), GEICAM (Martín et al., 2017) and I-SPY (Cureton et al., 2014)) included RCB as

a primary or secondary end point for response to NAC. Among the variety of scoring systems developed in the last years (CPS (Jeruss et al., 2008a), CPS+EG, Neobioscore (Mittendorf et al., 2016) RCB index was recommended by the BIG-NABCG (Breast International Group-North American Breast Cancer Group) to quantify residual disease in neoadjuvant trials, in addition to pCR (Bossuyt et al., 2015). However, so far, it remains unknown if RCB index displays high prognostic performances in routine practice, and external fully independent validation of the prognostic value of the RCB index is lacking. The current study aims at evaluating the prognostic value of the RCB index in a large real-life cohort of breast cancer patients treated with NAC.

## **MATERIAL AND METHODS**

### Patients and tumors

The analysis was performed on a cohort of patients with invasive breast carcinoma stage T1-T3N<sub>x</sub>M0 and treated with NAC at Institut Curie, Paris, between 2002 and 2012 (NEOREP Cohort, CNIL declaration number 1547270). We included unilateral, non-recurrent, non-inflammatory, non-metastatic tumors, excluding T4 tumors. All patients received NAC, followed by surgery and radiotherapy. NAC regimens changed over our recruitment period (anthracycline-based regimen or sequential anthracycline-taxanes regimen), with trastuzumab used in an adjuvant and/or neoadjuvant setting since 2005. Endocrine therapy (tamoxifen or aromatase inhibitor) was prescribed when indicated. The study was approved by the Breast Cancer Study Group of Institut Curie and was conducted according to institutional and ethical rules regarding research on tissue specimens and patients. Written informed consent from the patients was not required by French regulations.

### Tumor samples

Cases were considered estrogen receptor (ER) or progesterone receptor (PR) positive (+) if at least 10% of the tumor cells expressed estrogen and/or progesterone receptors (ER/PR), in accordance with guidelines used in France (Harvey et al., 1999). *HER2* expression was determined by immunohistochemistry with scoring in accordance with American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Wolff et al., 2007). Scores 3+ were reported as positive, score 1+/0 as negative (-). Tumors with scores 2+ were further tested by FISH. *HER2* gene amplification was defined in accordance with ASCO/CAP guidelines (Wolff et al., 2007). We evaluated a mean of 40 tumor cells per sample and the mean *HER2* signals per nuclei was calculated. A *HER2*/CEN17 ratio  $\geq 2$  was considered positive, and a ratio  $< 2$  negative (Wolff et al., 2007). BC subtypes were defined as follows: tumors positive for either ER or PR, and negative for *HER2* were classified as luminal; tumors positive for *HER2* were considered to be *HER2*-positive BC; tumors negative for ER, PR, and *HER2* were considered to be triple-negative breast cancers (TNBC). Tumor cellularity was defined as the percentage of tumor cells (in situ and invasive) on the specimen (biopsy or surgical specimen). Mitotic index was reported per 10 high power fields (HPF) (1 HPF= 0.301 mm<sup>2</sup>).

### Pathological review

717 post-NAC pathological pretreatment core needle biopsies and the corresponding post-NAC surgical specimens were reviewed independently by two experts in breast diseases (ML, DD).

### *Residual Cancer Burden index*

Histological components of the “Residual Cancer Burden” were retrieved for calculating the score as described in 2007 by Symmans (see Supplementary Material). RCB index enables

the classification of residual disease into four categories: RCB-0 (complete pathologic response = pCR), RCB-I (minimal residual disease), RCB-II (moderate residual disease) and RCB-III (extensive residual disease). Two cutoff points defined those subgroups: the first (RCB-III v RCB-I/II) was selected as the 87th percentile (RCB, 3.28), and the second (RCB-I v RCB-II) corresponds to the 40th percentile (RCB, 1.36). RCB has been calculated through the web-based calculator that is freely available on the internet ([www.mdanderson.org/breastcancer\\_RCB](http://www.mdanderson.org/breastcancer_RCB)).

#### *TILs and LVI*

Lymphovascular invasion (LVI) was defined as the presence of carcinoma cells within a finite endothelial-lined space (a lymphatic or blood vessel). Tumor infiltrating lymphocytes (TILs) were defined as the presence of mononuclear cells infiltrate (including lymphocytes and plasma cells, excluding polymorphonuclear leukocytes), and were also evaluated retrospectively, for research purposes (see Supplementary Material).

#### Study endpoints

Relapse-free survival (RFS) was defined as the time from surgery to death, loco-regional recurrence or distant recurrence, whichever occurred first. Overall survival (OS) was defined as the time from surgery to death. The date of last known contact was retained for patients for whom none of these events were recorded. Survival cutoff date analysis was February, 1<sup>st</sup>, 2019.

#### Statistical analysis

The study population was described in terms of frequencies for qualitative variables, or medians and associated ranges for quantitative variables. Chi2 tests were performed to search for differences between subgroups for each variable (considered significant for p-values  $\leq$

0.05). Survival probabilities were estimated by the Kaplan–Meier method, and survival curves were compared in log-rank tests. Hazard ratios and their 95% confidence intervals were calculated with the Cox proportional hazards model. Variables with a p-value for the likelihood ratio test equal to 0.05 or lower in univariate analysis were selected for inclusion in the multivariate analysis. A forward stepwise selection procedure was used to establish the final multivariate model and the significance threshold was 5%. Missing data were present in 69 out of 717 patients (9.6%) for the variable lymphovascular invasion and we imputed these missing data by a chained equation multiple imputation strategy, as recommended in a previous study (Buuren and Groothuis-Oudshoorn, 2011). We assessed the effect of the RCB index both on the hazard scale (with a proportional hazards model) and on the log-of-time scale with an accelerated failure time model. Data were processed and statistical analyses were carried out with R software version 3.1.2 ([www.cran.r-project.org](http://www.cran.r-project.org), (R Foundation for Statistical Computing, 2009)).

## RESULTS

### *Patients' characteristics*

A total of 717 patients were included in the cohort. Patients and tumors characteristics are summarized in Table 1. Median age was 48 years old (range [25-80]) and most of the patients (63%) were premenopausal. BC repartition by subtype was as follows: luminal (n=222; 31%), TNBC (n=319; 44.5%), *HER2*-positive (n=176; 24.5%). No difference was observed according to BC subtype regarding age, menopausal status, clinical tumor size nor clinical nodal status. TNBC and *HER2*-positive BCs were associated with a higher grade, Ki67 and mitotic index than luminal BCs ( $p < 0.001$ ).

### *RCB index repartition and patients' characteristics by RCB class*



At NAC completion, RCB-0 (pCR) was observed in 202 patients (28.2%). Among 515 patients with residual disease, RCB index repartition was as follows RCB-I: n=65 (9%), RCB-II: n=309 (43.1%) and RCB-III: n=141 (19.7%) (Table 2, Figure 1A). The RCB index distribution was significantly different by BC subtypes ( $p<0.001$ ) (Table 2, Fig.1B): luminal tumors were more likely to be classified as RCB-II (49.1%) or III (36.9%), whereas TNBC or *HER2*-positive BC were more likely to be RCB-0 or I (45.7% and 52.3% respectively) ( $p<0.001$ ). Only small subsets of TNBC and *HER2*-positive BCs were classified as RCB-III (13.2% and 8.5% respectively).

The distribution of the index was bimodal as previously described ((Symmans et al., 2007a)), and the 2 modes of the distribution strongly overlapped with the post-NAC nodal status (Figures 2A-B). Most of the patients with tumors classified as RCB-I were free from axillar nodal involvement, while the majority of patients with tumors classified as RCB-III had a node-positive disease (Figures 2C-D).

Patients' characteristics by RCB class are summarized in Table 2 and are represented in Figure 3. Among pre-NAC parameters, RCB class was significantly different by tumor size ( $p<0.001$ ) (Fig.3A), clinical nodal status ( $p<0.001$ ) (Figure 3B), pathological grade ( $p<0.001$ ) (Figure 3C), BMI ( $p<0.05$ ) (Figure 3D) and mitotic index ( $p<0.001$ ) (Figure 3E). Pre-NAC TILs were inversely associated with RCB ( $p<0.001$ ) (Figure 3F). Among the post-NAC parameters, higher RCB class was significantly correlated with the presence of LVI ( $p<0.001$ ; Figure 3G), nodal involvement ( $p<0.001$ ; Figure 3H), whereas post-NAC TILs were positively associated with RCB ( $p<0.001$ ; Figure 3I).

### ***Survival analyses***

With a median follow-up of 99.9 months, [range (9.3-184.2 months)], 205 patients experienced relapse, and 133 were deceased. Among the whole population, RCB was

significantly associated with RFS (Figure 4A), and this association was significant after both univariate analysis and multivariate analysis (Table 3). Eight-years relapse free survival was good in RCB-0 and RCB-I group (89.9%, CI [85.6 – 94.4] and 89.0% CI [80.7 – 98.2] respectively), whereas the prognosis was intermediate in RCB-II patients (67.8%, CI [62.4 – 73.5]) and poor in RCB-III patients (52.7%, CI [44.8 – 62.0]). Increasing RCB was associated with an increased risk of relapse (RCB-II versus RCB-0: HR=3.25 CI [2.1-5.1]  $p<0.001$  and RCB-III versus RCB-0: HR=5.6 CI [3.5-9.0]  $p<0.001$ ). The prognosis impact of the RCB index was significant in TNBC and *HER2*-positive BCs, but not in luminal BC (Fig. 4.B-D and supp. Tables 1-2-3) ( $P_{\text{interaction}}=0.05$ , though the interaction test failed to reach statistical significance after multivariate analysis ( $P_{\text{interaction}}=0.057$ )). In addition to the increased risk of relapse, RCB index was also significantly associated with an earlier time-to-relapse, as estimated by the AFT regression model (RCB II *versus* RCB 0 and I grouped, HR= 3.27, 95% CI [2.18- 4.91], RCB-III *versus* RCB 0 and I grouped, HR= 5.73, 95% CI [3.74- 8.76]  $p<0.001$ ), and this was true in TNBC and *HER2*-positive BCs ( $p<0.001$ ) but not in luminal BCs ( $p=0.06$ ). In TNBC, RCB-III class identified a group of patients with extremely poor prognosis, displaying a median relapse-free survival of 12.7 months. We also identified an interaction between post-NAC TILs and RCB class to predict RFS ( $P_{\text{interaction}}=0.03$ ). Post-NAC TILs had no prognostic impact on RFS in pCR, RCB-I and RCB-II subgroups, while post-NAC TILs had a poor prognostic impact (HR=1.019, [1.001-1.037]) in the RCB-III subgroup.

Overall survival analyses yielded similar results (Figure 5, Table 4, Supp. Tables 4-5-6). Together with BC subtype, RCB index was the only independent predictor of survival in the whole population.

## DISCUSSION:

In this retrospective reanalysis of 717 surgical specimens of BC patients treated with NAC with a long-term follow-up, we confirm the strong prognostic value of the RCB index.

RCB index was first created in 2007 by Symmans and colleagues on a cohort of 241 BC patients who completed NAC (Symmans et al., 2007a). In this study, patients had almost a two-fold increase in relapse risk for each unit of increase in the RCB index and it remained significantly associated with the risk of disease recurrence after multivariate analysis. Though RCB is a composite endpoint built upon 6 variables, this index was shown to be highly reproducible (Peintinger et al., 2015). Peintinger *et al.* retrospectively assessed RCB on a series of 100 pathology slides from BC cases treated by NAC, and the overall concordance was 0.93 (95%CI=0.91-0.95) after an independent review by five pathologists. However, so far, the prognostic value of the index was evaluated only in small studies ((Campbell et al., 2017; Cockburn et al., 2014; Corben et al., 2013; Lee et al., 2014; Romero et al., 2013; Sheri et al., 2015; Symmans et al., 2007a, 2017)(Supp. Table 7). To the best of our knowledge, we report here the largest fully independent cohort available with a long-term follow-up, with a notably high number of patients with TNBCs.

Several findings of our study are of interest. **First**, in line with the findings of Symmans and colleagues, we found that the prognosis of patients with RCB-I was not significantly different than the prognosis of patients whose tumor reached pCR (RCB-0). The latter finding confirms that the category of pCR patients, known to be at a very low-risk of relapse, could be extended to patients with minimal residual disease. **Second**, we also confirm the very poor prognosis of patients with RCB-III disease, particularly in TNBC patients where the post-NAC median RFS barely exceeded one year. The identification of poor-prognosis after NAC is of substantial importance, as data from the CREATE-X and the KATHERINE trials suggest

that these patients may benefit from the addition of adjuvant capecitabine (Masuda et al., 2017) in the TNBC subpopulation, or adjuvant TDM-1 in *HER2*-positive BCs respectively (von Minckwitz et al., 2019). In the latter trials, both second-line therapies were associated with a decrease of the recurrence risk, nearly reaching 50%. **Finally**, patients with RCB-II disease displayed an intermediate prognosis, and it remains unknown if they would benefit from additional therapies. As they represent 40% of the cohort, further prognostic subsetting using genomic signatures or additional clinical or pathological features should be of particular interest in this group.

In our cohort, RCB index displayed a strong discriminative power in TNBC and *HER2*-positive BC but not in luminal BCs, and we identified a trend towards an interaction ( $P_{\text{interaction}}=0.07$ ) between BC subtype and RCB class. This finding is consistent with the well-known fact that BC subtypes respond differentially to NAC (Rouzier et al., 2005), and that the prognostic value of pCR is greatest in aggressive tumor subtypes as TNBC or *HER2*-positive BC (Cortazar et al., 2014) (von Minckwitz et al., 2012) than in luminal BCs. Of note, Symmans and colleagues previously published the SET index signature assaying 165 genes from ER-related transcription. On a cohort of 131 patients with ER+ BC treated with prior neoadjuvant chemotherapy, both the RCB index and the SET index were independently predictive of the distant relapse risk and the elevated endocrine sensitivity was associated with reduced relapse risk when there was less than extensive RCB after chemotherapy. In this context, the validation of the SET index signature in an independent NAC-treated cohort would be of interest.

Last, our study opens new perspectives for further improvement of the RCB index. We recently demonstrated that the presence of lymphovascular invasion (LVI) after NAC was associated with a dramatically impaired relapse-free survival in a BC subtype-dependent manner (Hamy et al., 2018), and we show here that this feature adds an independent

prognostic information to the RCB in the whole population, and in every BC subtype but luminal BCs. We also previously pointed out an interaction between RCB and the presence of stromal immune infiltration after chemotherapy (Hamy et al., 2019), and identified an impaired prognostic impact of post-NAC TILs in the RCB-III subgroup. As immunotherapy is increasingly becoming part of the therapeutic strategy of breast cancer (Emens, 2018; Loi et al., 2016; McArthur et al., 2016; Nanda et al., 2017; Vonderheide et al., 2010), the combination of both patterns could be an efficient tool to select poor-prognostic patients likely to benefit from such innovative treatments.

## References:

1. Bossuyt, V., Provenzano, E., Symmans, W.F., Boughey, J.C., Coles, C., Curigliano, G., Dixon, J.M., Esserman, L.J., Fastner, G., Kuehn, T., et al. (2015). Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Ann. Oncol.* *26*, 1280–1291.
2. Buuren, S. van, and Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software* *45*, 1–67.
3. Campbell, J.I., Yau, C., Krass, P., Moore, D., Carey, L.A., Au, A., Chhieng, D., Giri, D., Livasy, C., Mies, C., et al. (2017). Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Breast Cancer Res. Treat.* *165*, 181–191.
4. Cockburn, A., Yan, J., Rahardja, D., Euhus, D., Peng, Y., Fang, Y., and Rumnong Sarode, V. (2014). Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. *Hum. Pathol.* *45*, 249–258.
5. Corben, A.D., Abi-Raad, R., Popa, I., Teo, C.H.Y., Macklin, E.A., Koerner, F.C., Taghian, A.G., and Brachtel, E.F. (2013). Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Comparison Between Classifications and Their Practical Application. *Archives of Pathology & Laboratory Medicine* *137*, 1074–1082.
6. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* *384*, 164–172.
7. Cureton, E.L., Yau, C., Alvarado, M.D., Krontiras, H., Ollila, D.W., Ewing, C.A., Monnier, S., and Esserman, L.J. (2014). Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). *Ann Surg Oncol* *21*, 2889–2896.
8. Dieci, M.V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T.M., Demaria, S., Castaneda, C., et al. (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Semin. Cancer Biol.* *52*, 16–25.

9. Emens, L.A. (2018). Breast Cancer Immunotherapy: Facts and Hopes. *Clin Cancer Res* 24, 511–520.
10. Hamy, A.-S., Lam, G.-T., Laas, E., Darrigues, L., Balezeau, T., Guerin, J., Livartowski, A., Sadacca, B., Pierga, J.-Y., Vincent-Salomon, A., et al. (2018). Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. *Breast Cancer Res. Treat.* 169, 295–304.
11. Hamy, A.-S., Bonsang-Kitzis, H., Croze, D.D., Laas, E., Darrigues, L., Topciu, L., Menet, E., Vincent-Salomon, A., Lerebours, F., Pierga, J.-Y., et al. (2019). Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy. *Clin Cancer Res clincanres.3017.2018*.
12. Harvey, J.M., Clark, G.M., Osborne, C.K., and Allred, D.C. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J. Clin. Oncol.* 17, 1474–1481.
13. Hatzis, C., Gould, R.E., Zhang, Y., Abu-Khalaf, M., Chung, G., Sanft, T., Hofstatter, E., DiGiovanna, M., Shi, W., Chagpar, A., et al. (2013). Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. *Cancer Res* 73, P6-06-37-P6-06–37.
14. Hylton, N.M., Gatsonis, C.A., Rosen, M.A., Lehman, C.D., Newitt, D.C., Partridge, S.C., Bernreuter, W.K., Pisano, E.D., Morris, E.A., Weatherall, P.T., et al. (2016). Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. *Radiology* 279, 44–55.
15. Jeruss, J.S., Mittendorf, E.A., Tucker, S.L., Gonzalez-Angulo, A.M., Buchholz, T.A., Sahin, A.A., Cormier, J.N., Buzdar, A.U., Hortobagyi, G.N., and Hunt, K.K. (2008a). Staging of Breast Cancer in the Neoadjuvant Setting. *Cancer Res* 68, 6477–6481.
16. Jeruss, J.S., Mittendorf, E.A., Tucker, S.L., Gonzalez-Angulo, A.M., Buchholz, T.A., Sahin, A.A., Cormier, J.N., Buzdar, A.U., Hortobagyi, G.N., and Hunt, K.K. (2008b). Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. *J. Clin. Oncol.* 26, 246–252.
17. Lee, S.M., Bae, S.K., Kim, T.H., Yoon, H.K., Jung, S.J., Park, J.S., and Kim, C.K. (2014). Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant

chemotherapy. *Clin Nucl Med* 39, 882–886.

18. Loi, S., Dushyanthen, S., Beavis, P.A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D.L., Giltnane, J.M., Estrada, M.V., et al. (2016). RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clin Cancer Res* 22, 1499–1509.
19. Martín, M., Chacón, J.I., Antón, A., Plazaola, A., García-Martínez, E., Seguí, M.A., Sánchez-Rovira, P., Palacios, J., Calvo, L., Esteban, C., et al. (2017). Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. *Oncologist*.
20. Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017). Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *New England Journal of Medicine* 376, 2147–2159.
21. McArthur, H.L., Diab, A., Page, D.B., Yuan, J., Solomon, S.B., Sacchini, V., Comstock, C., Durack, J.C., Maybody, M., Sung, J., et al. (2016). A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. *Clin Cancer Res* 22, 5729–5737.
22. Von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S.D., Eidtmann, H., Fasching, P.A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J. Clin. Oncol.* 30, 1796–1804.
23. Von Minckwitz, G., Huang, C.-S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N. Engl. J. Med.* 380, 617–628.
24. Mittendorf, E.A., Vila, J., Tucker, S.L., Chavez-MacGregor, M., Smith, B.D., Symmans, W.F., Sahin, A.A., Hortobagyi, G.N., and Hunt, K.K. (2016). The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. *JAMA Oncol* 2, 929–936.
25. Nanda, R., Liu, M.C., Yau, C., Asare, S., Hylton, N., Veer, L.V., Perlmutter, J., Wallace, A.M., Chien, A.J., Forero-Torres, A., et al. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. *JCO* 35, 506–506.



26. R Foundation for Statistical Computing (2009). R Development Core Team. R: A Language and Environment for Statistical Computing.
27. Romero, A., García-Sáenz, J.A., Fuentes-Ferrer, M., López Garcia-Asenjo, J.A., Furió, V., Román, J.M., Moreno, A., de la Hoya, M., Díaz-Rubio, E., Martín, M., et al. (2013). Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. *Ann. Oncol.* *24*, 655–661.
28. Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K.R., Stec, J., Ayers, M., Wagner, P., et al. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin. Cancer Res.* *11*, 5678–5685.
29. Sheri, A., Smith, I.E., Johnston, S.R., A'Hern, R., Nerurkar, A., Jones, R.L., Hills, M., Detre, S., Pinder, S.E., Symmans, W.F., et al. (2015). Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. *Ann. Oncol.* *26*, 75–80.
30. Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007a). Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. *Journal of Clinical Oncology* *25*, 4414–4422.
31. Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007b). Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* *25*, 4414–4422.
32. Symmans, W.F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017). Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. *J. Clin. Oncol.* *35*, 1049–1060.
33. Vonderheide, R.H., LoRusso, P.M., Khalil, M., Gartner, E.M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J.A., Rüter, J., Mariani, G.L., et al. (2010). Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. *Clin Cancer Res* *16*, 3485–3494.
34. Wolff, A.C., Hammond, M.E.H., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Fitzgibbons, P.L., Hanna, W.M., Langer, A., et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast

cancer. *J. Clin. Oncol.* 25, 118–145.

### **Fundings and acknowledgments:**

We thank Roche France for financial support for the construction of the Institut Curie neoadjuvant database (NEOREP). Funding was also obtained from the *Site de Recherche Intégrée en Cancérologie/Institut National du Cancer* (Grant No. INCa-DGOS-4654). A-S Hamy-Petit was supported by an ITMO-INSERM-AVIESAN translational cancer research grant. We thank Pr Aurelien Latouche for his helpful advice and for validating the statistical methodology used in this study.

## **TABLES' LEGENDS :**

**Table 1:** Patients' characteristics among the whole population and in each subtype. Missing values : menopausal status n= 7, BMI n=1, clinical nodal status n=1, mitotic index n=35, histology n=4, grade n=16, Ki67 n=538, LVI n=69.

Abbreviations: pCR=pathological complete response; BMI=body mass index; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines ; LVI=lymphovascular invasion ; RCB=residual cancer burden

**Table 2:** Patients' characteristics according to RCB classes.

Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines ; LVI=lymphovascular invasion, TILs=tumor infiltrating lymphocytes

**Table 3:** Association of clinical and pathological pre and post-NAC parameters with relapse-free survival after univariate and multivariate analysis in the whole population. Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines; TILs=tumor infiltrating lymphocytes; RCB=residual cancer burden; LVI=lymphovascular invasion

**Table 4:** Association of clinical and pathological pre and post-NAC parameters with overall survival after univariate and multivariate analysis in the whole population.

Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines; TILs=tumor infiltrating lymphocytes; RCB=residual cancer burden; LVI=lymphovascular invasion

**Table 1 : Patients' characteristics among the whole population and in each subtype.**

Missing values : menopausal status n= 7, BMI n=1, clinical nodal status n=1, mitotic index n=35, histology n=4, grade n=16, Ki67 n=538, LVI n=69.

Abbreviations: pCR=pathological complete response; BMI=body mass index; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines ; LVI=lymphovascular invasion ; RCB=residual cancer burden.

Characteristics	Class	All	Luminal	TNBC	HER2	p
<b>n=</b>		<b>717 (100%)</b>	<b>222 (31.0%)</b>	<b>319 (44.5%)</b>	<b>176 (24.5%)</b>	
<b>Pre-NAC characteristics</b>						
<b>Age (years)</b>	<45	285 (39.7%)	88 (39.6%)	119 (37.3%)	78 (44.3%)	0.531
	45-55	254 (35.4%)	82 (36.9%)	118 (37.0%)	54 (30.7%)	
	>55	178 (24.8%)	52 (23.4%)	82 (25.7%)	44 (25.0%)	
<b>Menopausal status</b>	pre	451 (63.5%)	146 (66.4%)	191 (60.6%)	114 (65.1%)	0.350
	post	259 (36.5%)	74 (33.6%)	124 (39.4%)	61 (34.9%)	
<b>BMI</b>	[19-25]	414 (57.8%)	121 (54.5%)	176 (55.3%)	117 (66.5%)	<b>0.046</b>
	<19	41 (5.7%)	18 (8.1%)	16 (5.0%)	7 (4.0%)	
	>25	261 (36.5%)	83 (37.4%)	126 (39.6%)	52 (29.5%)	
<b>Clinical tumor size</b>	T1	47 (6.6%)	10 (4.5%)	27 (8.5%)	10 (5.7%)	0.199
	T2	481 (67.1%)	160 (72.1%)	207 (64.9%)	114 (64.8%)	
	T3	189 (26.4%)	52 (23.4%)	85 (26.6%)	52 (29.5%)	
<b>Clinical nodal status</b>	N0	282 (39.4%)	79 (35.7%)	141 (44.2%)	62 (35.2%)	0.061
	N1-N2-N3	434 (60.6%)	142 (64.3%)	178 (55.8%)	114 (64.8%)	
<b>Histology</b>	NST	660 (92.6%)	199 (89.6%)	291 (92.1%)	170 (97.1%)	<b>0.017</b>
	others	53 (7.4%)	23 (10.4%)	25 (7.9%)	5 (2.9%)	
<b>Grade</b>	I-II	211 (30.1%)	119 (55.1%)	40 (12.8%)	52 (30.1%)	<b>&lt;0.001</b>
	III	490 (69.9%)	97 (44.9%)	272 (87.2%)	121 (69.9%)	
<b>Ki67</b>	<20	33 (18.4%)	8 (50.0%)	22 (15.5%)	3 (14.3%)	<b>0.003</b>
	≥20	146 (81.6%)	8 (50.0%)	120 (84.5%)	18 (85.7%)	
<b>Mitotic Index</b>	≤22	389 (57.0%)	153 (72.9%)	124 (41.2%)	112 (65.5%)	<b>&lt;0.001</b>
	>22	293 (43.0%)	57 (27.1%)	177 (58.8%)	59 (34.5%)	
<b>ER status</b>	negative	396 (55.2%)	0 (0.0%)	319 (100.0%)	77 (43.8%)	<b>&lt;0.001</b>
	positive	321 (44.8%)	222 (100.0%)	0 (0.0%)	99 (56.2%)	
<b>PR status</b>	negative	473 (68.2%)	43 (21.1%)	319 (100.0%)	111 (64.9%)	<b>&lt;0.001</b>
	positive	221 (31.8%)	161 (78.9%)	0 (0.0%)	60 (35.1%)	
<b>HER2 status</b>	negative	541 (75.5%)	222 (100.0%)	319 (100.0%)	0 (0.0%)	<b>&lt;0.001</b>
	positive	176 (24.5%)	0 (0.0%)	0 (0.0%)	176 (100.0%)	
<b>NAC regimen</b>	AC	61 (8.5%)	3 (1.4%)	54 (16.9%)	4 (2.3%)	<b>&lt;0.001</b>
	AC-Taxanes	576 (80.3%)	202 (91.0%)	222 (69.6%)	152 (86.4%)	
	others	80 (11.2%)	17 (7.7%)	43 (13.5%)	20 (11.4%)	
<b>Post-NAC characteristics</b>						
<b>RCB</b>	RCB-0	202 (28.2%)	11 (5.0%)	123 (38.6%)	68 (38.6%)	<b>&lt;0.001</b>
	RCB-I	65 (9.1%)	18 (8.1%)	23 (7.2%)	24 (13.6%)	
	RCB-II	309 (43.1%)	109 (49.1%)	131 (41.1%)	69 (39.2%)	
	RCB-III	141 (19.7%)	84 (37.8%)	42 (13.2%)	15 (8.5%)	
<b>Number of nodes involved</b>	0	445 (62.1%)	78 (35.1%)	238 (74.6%)	129 (73.3%)	<b>&lt;0.001</b>
	1-3	188 (26.2%)	100 (45.0%)	49 (15.4%)	39 (22.2%)	
	≥4	84 (11.7%)	44 (19.8%)	32 (10.0%)	8 (4.5%)	
<b>LVI</b>	no	500 (77.2%)	130 (66.0%)	232 (80.8%)	138 (84.1%)	<b>&lt;0.001</b>
	yes	148 (22.8%)	67 (34.0%)	55 (19.2%)	26 (15.9%)	

**Table 2: Patients' characteristics according to RCB classes.**

Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines ; LVI=lymphovascular invasion, TILs=tumor infiltrating lymphocytes.

Variable	Class	pCR	RCB-I	RCB-II	RCB-III	p
n=		202	65 (9.1%)	309	141	
Pre-NAC parameters						
Age (years)	<45	76 (37.6%)	31 (47.7%)	130	48 (34.0%)	0.13
	45-55	66 (32.7%)	25 (38.5%)	108	55 (39.0%)	
	>55	60 (29.7%)	9 (13.8%)	71 (23.0%)	38 (27.0%)	
Menopausal Status	pre	119	46 (71.9%)	202	84 (60.4%)	0.23
	post	80 (40.2%)	18 (28.1%)	106	55 (39.6%)	
BMI	19≤BMI≤2	125	46 (70.8%)	176	67 (47.5%)	0.00
	<19	8 (4.0%)	6 (9.2%)	15 (4.9%)	12 (8.5%)	
	>25	68 (33.8%)	13 (20.0%)	118	62 (44.0%)	
Tumoral Size	T1	26 (12.9%)	3 (4.6%)	12 (3.9%)	6 (4.3%)	<0.0
	T2	129	52 (80.0%)	213	87 (61.7%)	
	T3	47 (23.3%)	10 (15.4%)	84 (27.2%)	48 (34.0%)	
Nodal status	N0	83 (41.1%)	32 (49.2%)	138	29 (20.7%)	<0.0
pre NAC	N1-N2-N3	119	33 (50.8%)	171	111	
Mitotic Index	≤22	89 (47.1%)	40 (66.7%)	167	93 (68.4%)	0.00
	>22	100	20 (33.3%)	130	43 (31.6%)	
Histology	NST	188	59 (90.8%)	292	121	0.00
	other	13 (6.5%)	6 (9.2%)	14 (4.6%)	20 (14.2%)	
Grade	I-II	33 (16.8%)	21 (32.8%)	91 (30.2%)	66 (47.5%)	<0.0
	III	164	43 (67.2%)	210	73 (52.5%)	
Ki67	<20%	6 (10.2%)	3 (30.0%)	17 (20.7%)	7 (25.0%)	0.19
	≥ 20%	53 (89.8%)	7 (70.0%)	65 (79.3%)	21 (75.0%)	
TILs stromal	mean %	34	26.1	19.7	19.0	<0.0
Subtype	luminal	11 (5.4%)	18 (27.7%)	109	84 (59.6%)	<0.0
	TNBC	123	23 (35.4%)	131	42 (29.8%)	
	HER2	68 (33.7%)	24 (36.9%)	69 (22.3%)	15 (10.6%)	
ER status	negative	163	31 (47.7%)	152	50 (35.5%)	<0.0
	positive	39 (19.3%)	34 (52.3%)	157	91 (64.5%)	
PR status	negative	183	38 (60.3%)	185	67 (51.9%)	<0.0
	positive	17 (8.5%)	25 (39.7%)	117	62 (48.1%)	
HER2 status	negative	134	41 (63.1%)	240	126	<0.0
	positive	68 (33.7%)	24 (36.9%)	69 (22.3%)	15 (10.6%)	
NAC	AC	17 (8.4%)	3 (4.6%)	30 (9.7%)	11 (7.8%)	0.59
	AC-	158	57 (87.7%)	244	117	
	others	27 (13.4%)	5 (7.7%)	35 (11.3%)	13 (9.2%)	
Post-NAC parameters						
Nodal involvement	0	202	53 (81.5%)	188	2 (1.4%)	<0.0
	1-3	0 (0.0%)	12 (18.5%)	101	75 (53.2%)	
	≥4	0 (0.0%)	0 (0.0%)	20 (6.5%)	64 (45.4%)	
LVI	no	200	41 (91.1%)	190	69 (51.1%)	<0.0
	yes	2 (1.0%)	4 (8.9%)	76 (28.6%)	66 (48.9%)	
Mitotic Index	mean, SD		0.82 (2.54)	17.75	19.32	<0.0
TILs stromal	mean, SD	8.7 (10.5)	12.8 (14.6)	14.8 (12.5)	15.2 (14)	<0.0

**Table 3: Association of clinical and pathological pre and post-NAC parameters with relapse-free survival after univariate and multivariate analysis in the whole population.**

Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines; TILs=tumor infiltrating lymphocytes; RCB=residual cancer burden; LVI=lymphovascular invasion.

Variable	Class	Number	Events	Univariate			Multivariate			
				HR	CI	p*	p	HR	CI	p
Pre-NAC parameters										
Age (years)	<45	285	92	1						0.266
	45-55	254	67	0.81	[0.59 - 1.11]					
	>55	178	46	0.78	[0.55 - 1.11]					
Menopausal status	pre	451	127	1						0.796
	post	259	74	1.04	[0.78 - 1.38]					
BMI	19≤BMI≤25	414	111	1						0.348
	<19	41	11	1.01	[0.54 - 1.87]					
	>25	261	83	1.23	[0.93 - 1.64]					
Tumor size	T1	47	13	1						0.027
	T2	481	127	0.93	[0.53 - 1.65]	0.812				
	T3	189	65	1.41	[0.77 - 2.55]	0.263				
Clinical nodal status	N0	282	78	1						0.597
	N1-N2-N3	434	127	1.08	[0.81 - 1.43]					
Mitotic index	≤22	389	110	1						0.185
	>22	293	90	1.21	[0.91 - 1.6]					
Histology	NST	660	182	1						0.026
	other	53	22	1.65	[1.06 - 2.57]					
Grade	I-II	211	70	1						0.268
	III	490	131	0.85	[0.63 - 1.13]					
Ki67	<20 %	33	10	1						0.53
	≥20 %	146	51	1.24	[0.63 - 2.45]					
Subtype	luminal	222	75	1				1	-	-
	TNBC	319	102	1.1	[0.82 - 1.49]	0.523		2,13	[1.54 - 2.96]	<0.001
	HER2	176	28	0.46	[0.3 - 0.71]	<0.001		0,92	[0.58 - 1.45]	0,7
ER status	negative	396	112	1						0.516
	positive	321	93	0.91	[0.69 - 1.2]					
PR status	negative	473	135	1						0.26
	positive	221	59	0.84	[0.62 - 1.14]					
HER2 status	negative	541	177	1						<0.001
	positive	176	28	0.43	[0.29 - 0.65]					
NAC regimen	AC	61	25	1						0.115
	AC-Taxanes	576	161	0.66	[0.43 - 1]					
	Others	80	19	0.58	[0.32 - 1.06]					
TILs	(continuous)			0,99	[0.98-0.99]					0,002
Post-NAC parameters										
Nodal involment	0	445	86	1						<0.001
	1-3	188	69	2	[1.45 - 2.74]	<0.001				
	≥4	84	50	3.85	[2.71 - 5.45]	<0.001				
RCB class	pCR	202	23	1				1	-	-
	RCB-I	65	7	0.98	[0.42 - 2.3]	0.972		1,17	[0.50 - 2.74]	0.48
	RCB-II	309	102	3.25	[2.07 - 5.11]	<0.001		3,38	[2.11 - 5.39]	<0.001
	RCB-III	141	73	5.61	[3.51 - 8.97]	<0.001		6,29	[3.73 - 10.62]	<0.001
Interaction term RCB class*BC subtype										
Interaction term RCB class*Post-NAC TILs										
LVI	no	500	108	1				1	-	-
	yes	148	75	2.76	[2.06 - 3.71]	<0.001		1,55	[1.15 - 2.08]	0,004
TILs	(continuous)			1,01	[0.99 - 1.02]					0,311



**Table 4: Association of clinical and pathological pre and post-NAC parameters with overall survival after univariate and multivariate analysis in the whole population.**

Abbreviations: pCR=pathological complete response; BMI=body mass index ; NST= no special type ; ER=oestrogen receptor; PR=progesterone receptor; NAC=neoadjuvant chemotherapy; AC=anthracyclines; TILs=tumor infiltrating lymphocytes; RCB=residual cancer burden; LVI=lymphovascular invasion.

Variable	Class	Number	Events	Univariate			Multivariate			
				HR	CI	p*	p	HR	CI	p
Pre-NAC parameters										
Age (years)	<45	285	57	1			0.514			
	45-55	254	48	0.96	[0.65 - 1.41]					
	>55	178	28	0.77	[0.49 - 1.21]					
Menopausal status	pre	451	80	1			0.457			
	post	259	51	1.14	[0.8 - 1.62]					
BMI	19≤BMI≤25	414	74	1			0.837			
	<19	41	8	1.14	[0.55 - 2.36]					
	>25	261	51	1.1	[0.77 - 1.58]					
Tumor size	T1	47	8	1			<b>0.007</b>	1	-	-
	T2	481	78	0.92	[0.44 - 1.91]	0.823		0.74	[0.35 - 1.55]	0.422
	T3	189	47	1.64	[0.77 - 3.47]	0.197		1.23	[0.57 - 2.66]	0.594
Clinical nodal status	N0	282	48	1			0.463			
	N1-N2-N3	434	85	1.14	[0.8 - 1.63]					
Mitotic index	≤22	389	64	1			0.014			
	>22	293	66	1.54	[1.09 - 2.18]	<b>0.014</b>				
Histology	ductal	660	121	1			0.65			
	other	53	11	1.15	[0.62 - 2.14]					
Grade	I-II	211	36	1			0.291			
	III	490	94	1.23	[0.84 - 1.81]					
Ki67	<20	33	5	1			0.33			
	≥20	146	35	1.59	[0.62 - 4.07]					
Subtype	luminal	224	19	1			<b>&lt;0.001</b>	1	-	-
	TNBC	311	59	2.77	[1.65 - 4.65]	0.075		2.7	[1.8 - 4.05]	<b>&lt;0.001</b>
	HER2	181	3	0.24	[0.07 - 0.83]	<b>&lt;0.001</b>		0.51	[0.24 - 1.08]	0.078
ER status	negative	396	80	1			<b>0.049</b>			
	positive	321	53	0.71	[0.5 - 1]	<b>0.049</b>				
PR status	negative	473	93	1			0.052			
	positive	221	33	0.67	[0.45 - 1]	0.052				
HER2 status	negative	541	122	1			<b>&lt;0.001</b>			
	positive	176	11	0.25	[0.13 - 0.46]	<b>&lt;0.001</b>				
NAC regimen	AC	61	13	1			0.489			
	AC-Taxanes	576	110	0.96	[0.54 - 1.72]					
	Others	80	10	0.65	[0.29 - 1.49]					
TILs	(continuous)			0.99	[0.98-0.99]		<b>0,01</b>			
Post-NAC parameters										
Nodal involmment	0	445	51	1			<b>&lt;0.001</b>			
	1-3	188	46	2.1	[1.41 - 3.13]	<b>&lt;0.001</b>				
	≥4	84	36	4.24	[2.76 - 6.5]	<b>&lt;0.001</b>				
RCB class	pCR	202	12	1			<b>&lt;0.001</b>	1	-	-
	RCB-I	65	2	0.55	[0.12 - 2.45]	0.43		0.75	[0.17 - 3.38]	0.711
	RCB-II	309	68	3.85	[2.09 - 7.12]	<b>&lt;0.001</b>		4.17	[2.21 - 7.86]	<b>&lt;0.001</b>
	others	141	51	6.59	[3.51 - 12.37]	<b>&lt;0.001</b>		6.6	[3.28 - 13.27]	<b>&lt;0.001</b>
LVI	no	500	66	1			<b>&lt;0.001</b>	1	-	-
	yes	148	55	3.07	[2.15 - 4.39]	<b>&lt;0.001</b>		1.76	[1.21 - 2.57]	<b>0.003</b>
TILs	(continuous)			0.99	[0.99-1.02]		0,329			

## FIGURES' LEGENDS:

**Figure 1:** RCB class distribution among the whole population and by BC subtypes: A) among the whole population, B) in each subtype population


**Figure 2:** Histograms of the distribution of residual cancer burden (RCB) index in the patients with residual disease at surgery immediately following NAC, in the whole population (A) and according to phenotype of disease (C). Histograms showing the distribution of nodal status (positive or negative) according the RCB value, in the whole population (B) and according to the phenotype of disease (D)

**Figure 3:** Associations between RCB classes (pCR to RCB-III) and clinico-pathological variables: A) pre-NAC tumor size, B) Clinical Nodal status at baseline, C) Grade I to II tumors, D) BMI, E) pre-NAC mitotic index, F) Pre-NAC TILs, G) post-NAC LVI, H) pathological nodal involvement, I) post-NAC TILs.


**Figure 4:** Association of RCB classes (pCR to III) with relapse-free survival (RFS): A) whole population (N=717), B) TNBC (N=319), C) luminal tumors (N=222), D) HER2-positive BC (N=176)

**Figure 5:** Association of RCB classes (0 to III) with overall survival (OS): A) whole population (N=717), B) TNBC (N=319), C) luminal tumors (N=222), D) HER2-positive BC (N=176)


**Figure 1: RCB class distribution among the whole population and by BC subtypes: A) among the whole population, B) in each subtype population**




**Figure 2: Histograms of the distribution of residual cancer burden (RCB) index in the patients with residual disease at surgery immediately following NAC, in the whole population (A) and according to phenotype of disease (C). Histograms showing the distribution of nodal status (positive or negative) according the RCB value, in the whole population (B) and according to the phenotype of disease (D)**



**Figure 3: Associations between RCB classes (pCR to RCB-III) and clinico-pathological variables: A) pre-NAC tumor size, B) Clinical Nodal status at baseline, C) Grade I to II tumors, D) BMI, E) pre-NAC mitotic index, F) Pre-NAC TILs, G) post-NAC LVI, H) pathological nodal involvement, I) post-NAC TILs.**



**Figure 4: Association of RCB classes (pCR to III) with relapse-free survival (RFS): A) whole population (N=717), B) TNBC (N=319), C) luminal tumors (N=222), D) HER2-positive BC (N=176)**



**Figure 5: Association of RCB classes (0 to III) with overall survival (OS): A) whole population (N=717), B) TNBC (N=319), C) luminal tumors (N=222), D) HER2-positive BC (N=176)**

